Winchester, United Kingdom
July 13, 2015
Exosect Ltd., a leading provider of enabling technologies, today announced that it has received approval to import it’s isolate of the entomopathogenic fungus, Beauveria bassiana, into the USA. The isolate, has been selected for its ability to control a range of insect pests and Exosect has, over the past nine years, been developing the targeted delivery of this biological control agent as part of a European development programme, using its proprietary platform technology, Entostat.
Entostat, a patented electrostatic micro-powder, delivers biological and synthetic active ingredients. For this biological formulation, Entostat delivers an optimised formulation of spores and has so far been demonstrated as a structural treatment in stored grain silos. This development programme complements recent trials in grain where Entostat efficiently delivered Deltamethrin and Pirimyphos-methyl both separately and in co-formulation, at rates half that of conventional formulations.
A data package for this particular isolate of Beauveria bassiana is now under review with european regulators and is due to be approved in 2017. In the meantime, further trial work is underway to demonstrate further delivery application techniques using the Entostat platform, the first being an admixture formulation.
The import approval has been sought in the US to enable in country development. Exosect are currently seeking license partners for this technology and further country import approvals are expected in due course.
About Entostat
Entostat is an electrostatically charged micro-powder. A leading variant of Entostat is based on a carnauba wax blend that is chemically inert.
This variant of Entostat is sustainably harvested from the Brazilian Carnauba palm, Copernica martius (Palmae). Other variants include a range of natural and synthetic waxes and polymers.
Entostat is a non-hygroscopic electrostatic micro-powder that can be produced in a range of sizes and shapes. It can be formulated to microencapsulate synthetic active ingredients offering release retardation and to support biological active ingredients on its surface by electrostatic attraction.
Entostat readily gains an electrostatic charge, consequently it adheres to a range of surfaces including, grains and seeds, insects & animals, building fabrics.
It therefore has the potential to deliver active ingredients at a reduced application rate with equivalent or improved efficacy.
Entostat is a registered trademark of Exosect Ltd.
About Exosect
Exosect was launched in 2001 to develop proprietary platforms technologies, initially for agriculture.
The company has developed an in-depth knowledge and extensive patent portfolio of the platforms as targeted delivery mechanisms for a range of active ingredients, biological and synthetic.
Today, the technology is enabling our partners across a range of sectors to realise the efficient delivery of their active ingredients, helping them to overcome issues such as pest resistance, regulatory controls and residues within the food chain.
Exosect is focussed on the Agriculture, Public Health and Animal Health sectors.
Topics
Species
